Retinoblastoma

Rosettes of tumour cells in retinoblastoma
Rosettes of tumour cells in retinoblastoma
A cut eye with a white tumour inside
A cut eye with a white tumour inside

Table of Contents

  1. Overview
  2. Genetics and Two-Hit Hypothesis
  3. Clinical Presentation
  4. Diagnosis
  5. International Classification
  6. Treatment
  7. Prognosis and Outcomes
  8. Genetic Counseling and Surveillance
  9. Key Research Papers
  10. Connections
  11. Featured Videos

Overview

Retinoblastoma is the most common primary intraocular malignancy of childhood and represents a true ophthalmologic emergency. The tumor arises from immature retinal cells — specifically cone precursor cells in the developing retina — and occurs almost exclusively in young children. In the United States, approximately 300 new cases are diagnosed each year, with an incidence of roughly 1 in 15,000 to 20,000 live births. The peak age of diagnosis is 1 to 2 years, with 95% of cases identified before age 5. Retinoblastoma is rare in adults.

The disease falls into two broad categories. Hereditary retinoblastoma, accounting for 35–45% of cases, results from a germline mutation in the RB1 tumor suppressor gene and is characterized by bilateral or multifocal tumors with an earlier age of onset. Non-hereditary (sporadic) retinoblastoma accounts for 55–65% of cases, arises from two somatic mutations, and typically presents as unilateral, unifocal disease at a slightly older age.

Early diagnosis is life-saving. In high-income countries, survival rates exceed 95% because the disease is usually caught before it exits the eye. In low- and middle-income countries, where children often present with advanced orbital or metastatic disease, survival is lower: a global study of 4,064 children found 3-year survival of 57.3% in low-income countries and 80.3% in lower-middle-income countries. The simple act of checking a newborn's red reflex — the bright orange-red glow seen in a normal fundus photograph — can detect this disease early enough to save both the child's life and, increasingly, the eye itself.

Back to Table of Contents

Genetics and Two-Hit Hypothesis

The molecular story of retinoblastoma gave birth to one of the most influential concepts in cancer biology. In 1971, Alfred Knudson analyzed the statistics of retinoblastoma incidence and proposed that two mutational "hits" are required to abolish retinal cell control — the first in one RB1 allele and the second in the remaining normal copy. In hereditary cases, the first hit is inherited in every cell of the body, so only a single somatic second hit is needed in any susceptible retinal precursor cell, explaining why these patients develop multiple tumors early. In sporadic cases, both hits must occur independently in the same somatic cell — a far less probable event — explaining why these tumors are solitary and appear later.

The RB1 gene maps to chromosome 13q14 and encodes the retinoblastoma protein (pRb), a master regulator of the G1-to-S phase cell cycle checkpoint. When functional, pRb binds and inactivates the transcription factor E2F, preventing the cell from entering DNA synthesis. Loss of both RB1 alleles releases this brake, allowing uncontrolled proliferation of immature retinal cone precursor cells.

Hereditary retinoblastoma follows an autosomal dominant inheritance pattern at the family level, even though the cellular mechanism is recessive. A parent carrying one germline RB1 mutation faces a 50% transmission risk per pregnancy. Approximately 10–15% of unilateral cases without a family history carry a germline mutation (de novo or low-level mosaic), making genetic testing important even for apparently sporadic unilateral disease.

Children with germline RB1 mutations face a substantially elevated lifetime risk of second primary malignancies. Osteosarcoma is the most common second cancer, followed by soft tissue sarcomas, melanoma, and other epithelial tumors. Prior external beam radiation dramatically amplifies this risk — up to 20–35% cumulative incidence over 30 years in irradiated hereditary patients — which is one reason modern management has shifted strongly toward radiation-sparing approaches. Pinealoblastoma, an aggressive midline brain tumor arising from the pineal gland, complicates approximately 5% of bilateral hereditary cases and is called "trilateral retinoblastoma." A 2015 meta-analysis gives 5.3% of children with bilateral retinoblastoma across all cohorts and 3.8% after leaving out cohorts of fewer than 100 patients, for trilateral disease at any site. Its appearance on neuroimaging is a grave prognostic sign. A distinct molecular subset of aggressive unilateral retinoblastoma is driven by MYCN amplification rather than RB1 loss; these tumors typically occur in infants under 1 year and follow a more aggressive course.

Back to Table of Contents

Clinical Presentation

The most common presenting sign of retinoblastoma — seen in approximately 60% of patients — is leukocoria: an absent or white-appearing red reflex in one or both eyes, colloquially called "white pupil" or "cat's eye reflex." Parents or primary care clinicians often first notice it in photographs, where the camera flash illuminates the tumor instead of the normal orange fundus reflex. This is why the American Academy of Pediatrics recommends checking the red reflex at every well-child visit from birth through early childhood.

Strabismus (misalignment of the eyes) is the second most common presenting sign, at 10.2% in a global study of 4,351 new patients, after leukocoria (62.8%) and ahead of proptosis, a bulging eye (7.4%). When a tumor involves the fovea or macula, it disrupts central vision in that eye and the visual system loses the normal binocular fixation mechanism, causing the eye to drift. New-onset strabismus in a child is therefore a recognized reason for a dilated fundus examination, which can show or rule out an intraocular mass before a benign cause is assumed.

Other presenting features include decreased vision (which young children cannot articulate), a red and painful eye from neovascular glaucoma caused by tumor-released angiogenic factors, rubeosis iridis (new vessels on the iris surface), heterochromia, and hyphema (blood in the anterior chamber). In advanced cases, orbital extension produces proptosis, periorbital swelling, and an appearance that can mimic orbital cellulitis. Prompt distinction is critical because orbital cellulitis is treated with antibiotics whereas orbital retinoblastoma requires urgent oncologic intervention.

Because the hereditary form is bilateral in the majority of affected individuals, screening examinations under anesthesia starting at birth, before symptoms ever develop, are described for any child in a family with a known RB1 mutation. The 2018 consensus report of the American Association of Ophthalmic Oncologists and Pathologists recommends dedicated eye screening for all children at risk above the population risk.

Back to Table of Contents

Diagnosis

The diagnostic workup is coordinated by a pediatric ophthalmologist with expertise in ocular oncology, ideally at a specialized retinoblastoma center. The cornerstone is examination under anesthesia (EUA) with dilated binocular indirect ophthalmoscopy, which allows a complete map of the retinal surface in both eyes, precise measurement of tumor size and location, identification of subretinal fluid, and documentation of vitreous or subretinal seeding. EUA is performed under general anesthesia because the examination requires complete immobility and full dilation, which is impossible to achieve reliably in infants and toddlers when awake.

The characteristic ophthalmoscopic finding is a white, chalky, elevated retinal mass, often with calcification visible as bright white flecks. Associated retinal detachment — either focal or total — is common. B-scan ocular ultrasonography confirms the intraocular location of the mass and demonstrates hyperreflective calcifications that cast acoustic shadows, a finding highly specific for retinoblastoma among all childhood leukocoria causes.

Computed tomography (CT) of the head and orbits readily demonstrates calcification within the globe, which is present in approximately 95% of retinoblastomas and helps differentiate it from other causes of leukocoria such as Coats disease, persistent fetal vasculature, or toxocariasis. However, computed tomography delivers ionizing radiation to the lens and brain, which is a particular concern in children with hereditary RB1 mutations who are already predisposed to radiation-induced second malignancies. Magnetic resonance imaging (MRI) of the orbits and brain with gadolinium contrast has become the preferred advanced imaging modality: it evaluates optic nerve involvement, choroidal invasion depth, extraocular extension into the orbit, and — critically — the pineal gland and suprasellar region for trilateral disease.

Crucially, trans-vitreal needle biopsy of the intraocular tumor is absolutely contraindicated because it risks seeding tumor cells into the orbit and subconjunctival space, dramatically worsening prognosis. Lumbar puncture and bone marrow examination are reserved for patients with clinical or imaging evidence of extraocular or metastatic disease. Systemic staging workup — including magnetic resonance imaging of the brain and spine, bone marrow biopsy, and lumbar puncture for cerebrospinal fluid (CSF) cytology — is performed when extraocular spread is suspected.

Back to Table of Contents

International Classification

Treatment planning relies on the International Intraocular Retinoblastoma Classification (IIRC), which stratifies tumors into five groups (A through E) based on features that predict the likelihood of globe salvage with chemotherapy and focal therapy. The system replaced older classifications that were less predictive of modern treatment outcomes.

Group A encompasses the most favorable tumors: small, discrete retinal masses measuring 3 mm or less in greatest dimension, located at least 3 mm from the fovea and 1.5 mm from the optic disc, with no subretinal fluid or vitreous seeding. These are treated with focal therapies alone and carry the highest rates of visual preservation.

Group B includes tumors larger than 3 mm, or smaller tumors located close to the fovea or optic disc where focal therapy risks collateral damage to central vision, or any tumor associated with subretinal fluid extending less than 3 mm from the tumor margin.

Group C designates tumors with focal seeding: small, discrete clusters of tumor cells in the subretinal space or vitreous cavity directly adjacent to the primary tumor. Seeding confined to one quadrant of the vitreous or subretinal space falls in this group.

Group D represents the most advanced intraocular disease still amenable to globe-salvaging therapy: diffuse vitreous seeding throughout multiple quadrants, or diffuse subretinal seeding covering more than one quadrant of the retinal surface. Globe salvage rates for Group D are lower and differ by treatment. With intra-arterial chemotherapy, a 70-eye series reports salvage in 94% of the 17 Group D eyes treated first with it, and a series of 112 Group D eyes reports 78.6% overall and 85.1% in previously untreated eyes; both come from single centers. A 2006 series of systemic chemoreduction reports 47%. Treatment requires aggressive multi-agent approaches.

Group E defines eyes with massive tumors occupying more than two-thirds of the vitreous cavity, presence of neovascular glaucoma, opaque media precluding accurate tumor assessment, anterior segment invasion (tumor in the anterior chamber, iris, or ciliary body), or diffuse infiltrating retinoblastoma. Enucleation is generally recommended for Group E eyes because globe salvage is both unlikely and potentially dangerous given the risk of understaging a high-risk pathology specimen.

Extraocular disease is staged by the International Retinoblastoma Staging Working Group system: Stage 0 (tumor confined to eye, not enucleated), Stage I (enucleated, completely resected), Stage II (enucleated, microscopic residual disease), Stage III (regional extension to orbit, preauricular nodes, or cervical nodes), and Stage IV (distant metastasis, including central nervous system (CNS), bone marrow, or other organs).

Back to Table of Contents

Treatment

Retinoblastoma is an ophthalmologic emergency. Any delay in initiating treatment risks tumor growth, loss of the eye, and, in advanced cases, loss of life. Treatment is individualized based on IIRC group, laterality (unilateral vs. bilateral), the status of the fellow eye, the child's overall systemic health, and the institutional expertise available.

Focal Therapies

Small tumors (Groups A and B) can often be controlled with focal therapies alone, avoiding systemic chemotherapy and its associated toxicities. Laser photocoagulation uses a focused argon or diode laser to destroy the tumor's blood supply. Transpupillary thermotherapy (TTT) uses infrared laser energy to heat tumor cells to sublethal temperatures, inducing apoptosis. Cryotherapy uses a triple freeze-thaw cycle applied transsclerally to destroy tumors in the retinal periphery. These modalities are often combined and may require multiple sessions under general anesthesia.

Intra-Arterial Chemotherapy (IAC)

Intra-arterial chemotherapy — also called ophthalmic artery chemosurgery — has transformed the management of Groups B through D retinoblastoma over the past two decades. An interventional neuroradiologist inserts a microcatheter via the femoral artery, navigates it to the internal carotid artery, and superselectively places the tip in the ophthalmic artery, delivering high concentrations of chemotherapy directly into the eye's blood supply while minimizing systemic exposure. Melphalan is the primary agent; it is frequently combined with topotecan and sometimes carboplatin. Globe salvage rates of approximately 75% for Groups B through D have been reported by high-volume centers. Complications include neutropenia, retinal artery spasm, and, rarely, cerebrovascular events.

In a small single-center retrospective series of 17 children younger than 3 months or weighing under 6 kg, all were alive at a mean follow-up of 4 years and all eyes were saved, with no case of chemotherapy-related fever and neutropenia and no transfusion.

Systemic Chemotherapy

Systemic chemotherapy — classically the CRB regimen (carboplatin, vincristine, and etoposide, sometimes called CEV) — remains the standard of care for bilateral disease where both eyes require treatment simultaneously, for patients with extensive vitreous seeding not amenable to IAC, and for extraocular or metastatic disease. Carboplatin causes cumulative ototoxicity, which is monitored with serial audiograms. Etoposide carries a small but real risk of treatment-related leukemia.

Intravitreal Chemotherapy

For vitreous seeds — historically the most challenging component of retinoblastoma management and a major cause of treatment failure — direct intravitreal injection of melphalan or topotecan delivers high drug concentrations to the vitreous compartment. Modern injection technique uses a very small gauge needle with immediate cryotherapy at the injection site to prevent extraocular seeding, a concern that initially made clinicians reluctant to use this approach. Intravitreal chemotherapy has dramatically improved vitreous seed control rates and, combined with IAC, has made globe salvage possible in many Group D eyes. In a 2026 report from four referral centers in the USA and Europe, the experts describe growing use of both intra-arterial and intravitreal chemotherapy and state that high-dose topotecan is "becoming the standard approach" for vitreous seeds, anterior chamber tumor and recurrent retinal and subretinal tumors.

Enucleation

Surgical removal of the eye remains the definitive curative treatment for Group E disease and for eyes that have failed all eye-salvaging therapies. Performed correctly, enucleation is curative for intraocular retinoblastoma. A spherical orbital implant is placed at the time of surgery to maintain the volume of the orbit and support a prosthetic eye. Pathologic examination of the enucleated globe is essential: high-risk features including massive choroidal invasion, post-laminar optic nerve involvement, and anterior segment invasion indicate a need for adjuvant systemic chemotherapy to prevent metastasis.

Radiation

External beam radiotherapy (EBRT) was once a mainstay of retinoblastoma treatment but is now largely avoided, particularly in children with hereditary RB1 mutations, because of the profound long-term risk of radiation-induced second malignancies in the field. Plaque brachytherapy — a radioactive iodine-125 or ruthenium-106 disc sutured to the sclera overlying a focal tumor — remains useful for select recurrences and avoids the scatter radiation of EBRT.

High-Dose Chemotherapy with Autologous Stem Cell Rescue

For children with trilateral retinoblastoma or metastatic disease, high-dose chemotherapy followed by autologous stem cell rescue (HDC-ASCR) has improved outcomes compared to standard-dose regimens. Intensive multi-agent induction is followed by myeloablative conditioning and stem cell infusion to restore bone marrow function. Even with this aggressive approach, trilateral retinoblastoma carries a poor prognosis, though survival rates have improved markedly compared to the near-uniformly fatal outcomes seen in older series.

Back to Table of Contents

Prognosis and Outcomes

In high-income countries, the overall survival rate for retinoblastoma exceeds 95%, making it among the most curable of all childhood cancers when caught early and treated at experienced centers. This excellent survival reflects the fact that most children in these settings present with disease confined to the eye, before it has had the opportunity to spread along the optic nerve to the brain or through the bloodstream to bone, liver, or bone marrow. When disease remains intraocular, cure is essentially the rule.

Visual outcomes depend heavily on tumor location and IIRC group at presentation. Children with Group A disease retain functional vision in 90–95% of cases. Those with Group D disease — even when the globe is saved — frequently lose significant central vision because the fovea or optic nerve was involved by tumor or treatment. Globe salvage figures differ by treatment. With intra-arterial chemotherapy as first treatment, a 70-eye series reports 100% for Group B (1 eye), 100% for Group C (4 eyes), 94% for Group D (17 eyes) and 36% for Group E (14 eyes). With systemic chemoreduction, a 2006 series of 249 eyes reports 100% for Group A, 93% for Group B, 90% for Group C and 47% for Group D (Group E eyes had enucleation), and a 2026 review gives intravenous chemotherapy figures of 96%, 90%, 90%, 68% and 32% for Groups A to E.

Saving the eye does not always save sight. In a single-center review of intra-arterial chemotherapy, 23 of the 27 eyes (85.2%) in which vision could be measured had very poor vision (1.0 logMAR or worse), 10 of them with no light perception. All four better-seeing eyes had a healthy fovea at diagnosis, and 16 of 71 eyes (22.5%) developed a blockage of the blood vessels in the choroid (choroidal occlusive vasculopathy).

In low- and middle-income countries, the picture is starkly different. A landmark global study published in JAMA Oncology (2020) reported how late children reach care: in low-income countries 49.1% had extraocular disease and 18.9% had metastasis at diagnosis, against 0.3% with metastasis in high-income countries. The follow-up study in Lancet Global Health (2022) found 3-year survival of 57.3% in low-income, 80.3% in lower-middle-income, 91.2% in upper-middle-income and 99.5% in high-income countries. Lack of awareness among parents and primary care providers, limited access to pediatric ophthalmology, and delays in obtaining definitive treatment all contribute to late presentation and higher mortality in these settings. A 2024 survey of 145 countries found intravenous chemotherapy available in 95.9%, intravitreal chemotherapy in 69.7%, intra-arterial chemotherapy in 47.6% and genetic testing in 51.0%, with eye-preserving treatments still concentrated in higher-income settings.

For children with hereditary RB1 mutations, long-term surveillance is critical because of the substantial lifetime risk of second primary malignancies. In patients who received external beam radiation, this cumulative risk can reach 20–35% by 30 years after treatment. Even without radiation, hereditary retinoblastoma survivors face a 10–15% lifetime risk of second cancers, predominantly osteosarcoma. In a US cohort of 1,601 survivors, the cumulative incidence of a new cancer at 50 years after diagnosis was 36% in hereditary and 5.7% in non-hereditary patients, and radiation raised the risk in hereditary patients 3.1-fold. In 952 irradiated survivors of hereditary retinoblastoma, the 60-year cumulative incidence of head and neck sarcoma was 6.8% for bone and 9.3% for soft tissue; soft-tissue sarcoma of the body and limbs was rare until age 30, then rose steeply, reaching 6.6% at 60 years (9.4% in females).

Regular surveillance with whole-body magnetic resonance imaging and orthopedic assessment is used by some retinoblastoma centers for these patients throughout adolescence and adulthood, and surveillance practices vary widely by center. The 2020 international recommendations for adult survivors state that evidence supporting routine testing of survivors without symptoms was not identified; only skin examination for melanoma and prompt evaluation of head and neck symptoms were judged prudent.

Trilateral retinoblastoma, historically associated with survival rates below 10%, has improved with modern high-dose chemotherapy and autologous stem cell rescue, though it remains a life-threatening complication: in a meta-analysis of 174 patients, 5-year survival after pineal disease rose from 6% in those diagnosed before 1995 to 44% in those diagnosed from 1995 on. Surveillance brain magnetic resonance imaging every 3–6 months for the first 3 years after diagnosis is used for children with bilateral hereditary retinoblastoma to look for pinealoblastoma at its earliest, most treatable stage. A 2020 meta-analysis calls the evidence on the usefulness of this screening unclear: a scan every 6 months up to 36 months of age would take at least 311 scans to detect one case without symptoms and 776 to save one life, and 21 of 22 cases without symptoms (95%) were diagnosed before 40 months of age. It rates its level of evidence as low.

Back to Table of Contents

Genetic Counseling and Surveillance

Genetic counseling is an integral part of retinoblastoma management for every family. The implications of RB1 germline mutation status extend to the patient themselves (lifetime second-cancer risk, surveillance needs), their siblings (who may be at risk), and their future children (50% transmission risk if germline mutation is confirmed).

Next-generation sequencing of the RB1 gene — from blood for germline testing and from tumor tissue for somatic analysis — is now standard practice. Sequencing detects point mutations, small insertions/deletions, and splice site variants. Multiplex ligation-dependent probe amplification (MLPA) or chromosomal microarray detects large deletions and duplications that may be missed by sequencing alone. Together, these methods identify a pathogenic germline variant in approximately 95% of bilateral cases and 10–15% of unilateral cases.

Low-level somatic mosaicism for RB1 mutation presents a counseling challenge: the parent appears to have unilateral disease or is even unaffected clinically, yet they carry the mutation in a proportion of their cells sufficient to pass it to offspring. Sensitive next-generation sequencing with deep coverage and digital polymerase chain reaction (PCR) can detect mosaic allele fractions as low as 1–2%.

Surveillance protocols vary by risk category. The 2018 consensus report stratifies examination schedules into high-, intermediate- and low-risk children, with more frequent screening for high-risk children, which may preferentially be examinations under anesthesia. One schedule described for siblings of a proband with bilateral disease or a known germline mutation is examination under anesthesia at birth and at regular intervals (every 2–3 months for the first year, then every 3–4 months until age 3, then annually until age 7). Offspring of a germline mutation carrier face a 50% risk and are placed in the same intensive newborn screening program. Children with unilateral disease and no family history who test negative for a germline mutation on sensitive testing have a very low residual risk and generally do not require intensive family screening, though first-degree relatives benefit from a single dilated fundus examination.

MYCN-amplified retinoblastoma is a molecularly distinct entity that does not involve RB1 and does not confer the same hereditary cancer predisposition. Tumors in this subset tend to be large and poorly differentiated at presentation, affecting infants under 12 months with unilateral disease. Testing for MYCN amplification by fluorescence in situ hybridization (FISH) on enucleated specimens is becoming standard practice, as it identifies a subset that may require more aggressive treatment. In a study of 1,068 unilateral tumors without family history, 29 (2.7%) had no RB1 mutation and 15 of those had MYCN amplification; median age at diagnosis was 4.5 months in children with these tumors, against 24 months with RB1-mutated unilateral tumors. Enrollment in international retinoblastoma registries (such as the Children's Oncology Group and the International Society of Paediatric Oncology registries) is encouraged at all specialized centers to advance knowledge of rare presentations and optimize treatment protocols globally.

Back to Table of Contents

Key Research Papers

  1. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68(4):820–823 — PubMed PMID: 5279523 — The landmark paper introducing the two-hit hypothesis, based on statistical analysis of retinoblastoma incidence in hereditary vs. sporadic cases. Established the conceptual foundation for tumor suppressor gene biology.
  2. Dimaras H, Kimani K, Dimba EA, et al. Retinoblastoma. Lancet. 2012;379(9824):1436–1446 — PubMed PMID: 22414599 — Comprehensive review covering epidemiology, molecular pathogenesis, clinical presentation, management, and global disparities in retinoblastoma outcomes, with emphasis on low- and middle-income country settings.
  3. Shields CL, Mashayekhi A, Au AK, et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology. 2006;113(12):2276–2280 — PubMed PMID: 16996605 — Validated the IIRC grouping system by demonstrating its predictive value for globe salvage rates with systemic chemoreduction and focal therapy in a noncomparative case series of 249 eyes (success in 100%, 93%, 90% and 47% of Groups A to D).
  4. Abramson DH, Marr BP, Dunkel IJ, et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol. 2012;96(4):499–502 — PubMed PMID: 22053101 — Reported outcomes of ophthalmic artery chemosurgery in the most challenging intraocular retinoblastoma cases, demonstrating high rates of vitreous seed control and globe salvage previously thought unachievable (76 eyes; 2-year salvage in previously untreated eyes of 83%, 64% and 80% by type of seeding).
  5. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398–1404 — PubMed PMID: 18342944 — Early outcomes series establishing intra-arterial melphalan delivery as a globe-salvaging alternative to enucleation for advanced intraocular retinoblastoma in a high-volume center (7 of the first 9 eyes avoided enucleation).
  6. Shields CL, Bianciotto CG, Jabbour P, et al. Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol. 2011;129(11):1399–1406 — PubMed PMID: 21670328
  7. Fabian ID, Sagoo MS. Understanding retinoblastoma: epidemiology and genetics. Community Eye Health. 2018;31(101):7 — PubMed PMID: 29915458
  8. Skalet AH, Gombos DS, Gallie BL, et al. Screening children at risk for retinoblastoma: consensus report from the American Association of Ophthalmic Oncologists and Pathologists. Ophthalmology. 2018;125(3):453–458 — PubMed PMID: 29056300 — Consensus guidelines on surveillance protocols for children at genetic risk for retinoblastoma, including exam frequency by age and risk category, developed by the leading North American expert consortium.
  9. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. J Clin Oncol. 1995;13(4):902–909 — PubMed PMID: 7707117 — Demonstrated the activity of etoposide-carboplatin combinations in extraocular retinoblastoma, informing multi-agent systemic chemotherapy regimens used in advanced and metastatic disease (phase II study of 20 patients, 85% response).
  10. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272–2279 — PubMed PMID: 15800318 — Long-term follow-up of hereditary retinoblastoma survivors documenting the markedly elevated risk of second malignancies, particularly sarcomas, in radiation-treated patients — the key evidence driving modern radiation-avoidance strategies.
  11. Kivelä T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 2009;93(9):1129–1131 — PubMed PMID: 19704035 — Editorial on the global epidemiology of retinoblastoma, the most common eye cancer in children, which is reported to receive far less research attention and resources than adult eye diseases.
  12. Dimaras H, Corson TW, Cobrinik D, et al. Retinoblastoma. Nat Rev Dis Primers. 2015;1:15021 — PubMed PMID: 27189421
  13. Global Retinoblastoma Study Group, Fabian ID, Abdallah E, Abdullahi SU, et al. Global retinoblastoma presentation and analysis by national income level. JAMA Oncol. 2020;6(5):685–695 — PubMed PMID: 32105305 — Multinational study of 4,351 new patients from 153 countries showing dramatic disparities in stage at presentation by country income level.
  14. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Lancet Glob Health. 2022;10(8):e1128–e1140 — PubMed PMID: 35839812
  15. Munier FL, Gaillard MC, Balmer A, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–1083 — PubMed PMID: 22694968 — Presented the safety data and injection technique modifications (cryotherapy seal at needle entry site) that enabled direct intravitreal melphalan injections to become a standard tool for vitreous seed control, transforming the management of Group C and D disease.
  16. Shields CL, Manjandavida FP, Lally SE, et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–1460 — PubMed PMID: 24656794
  17. Abramson DH, Daniels AB, Marr BP, et al. Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma. PLoS One. 2016;11(1):e0146582 — PubMed PMID: 26756643
  18. Abramson DH, Francis JH, Knopman J, et al. Ophthalmic artery chemosurgery for retinoblastoma babies less than 3 months old or under 6-kg weight. Ophthalmol Retina. 2025;9(9):908–914 — PubMed PMID: 40120678
  19. Solera-de-Andrés C, Spang-Valencia P, Peralta-Calvo J. Severe visual loss and ocular complications after intra-arterial chemotherapy for retinoblastoma. Br J Ophthalmol. 2026;110(7):759–763 — PubMed PMID: 41475972
  20. Abramson DH, Shields CL, Munier FL, et al. How we approach intraocular retinoblastoma in 2026: agreement and disagreement in four referral centers in the USA and Europe. Pediatr Blood Cancer. 2026;73(8):e70401 — PubMed PMID: 42136006
  21. Shields CL, Medina RJ, Botros S, et al. Retinoblastoma management: achieving high standards of care. Eye (Lond). 2026 — PubMed PMID: 42839089
  22. Global Retinoblastoma Study Group. Global retinoblastoma service availability in 2024 and equity trends since 2017. Br J Ophthalmol. 2026 — PubMed PMID: 42463304
  23. Tonorezos ES, Friedman DN, Barnea D, et al. Recommendations for long-term follow-up of adults with heritable retinoblastoma. Ophthalmology. 2020;127(11):1549–1557 — PubMed PMID: 32422154
  24. Kleinerman RA, Schonfeld SJ, Sigel BS, et al. Bone and soft-tissue sarcoma risk in long-term survivors of hereditary retinoblastoma treated with radiation. J Clin Oncol. 2019;37(35):3436–3445 — PubMed PMID: 31622129
  25. de Jong MC, Kors WA, Moll AC, et al. Screening for pineal trilateral retinoblastoma revisited: a meta-analysis. Ophthalmology. 2020;127(5):601–607 — PubMed PMID: 32061409
  26. de Jong MC, Kors WA, de Graaf P, et al. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 2014;15(10):1157–1167 — PubMed PMID: 25126964
  27. de Jong MC, Kors WA, de Graaf P, et al. The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(6):1116–1126 — PubMed PMID: 26374932
  28. Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 2013;14(4):327–334 — PubMed PMID: 23498719

Search PubMed: Retinoblastoma Treatment
Search PubMed: Retinoblastoma RB1 Genetics
Search PubMed: Retinoblastoma Intra-Arterial Chemotherapy

Back to Table of Contents

Connections

Back to Table of Contents